Evidence map›Paper›PMID 42402487›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026

Reduced expression of N-methyl-D-aspartate receptor and calcium signaling genes in gray matter is associated with cancer-related cognitive impairment.

Shelli R Kesler, Oscar Y Franco-Rocha, Manuela Kogon, Sarah Braun, Leah Tolby, Ruth Nyagaka, Alexa De La Torre Schutz, Douglas W Blayney, Oxana Palesh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Shelli R KeslerLivestrong Cancer Institute, Dell School of Medicine, University of Texas at Austin, 1710 Red River St, Austin, TX, 78723, USA. srkesler@austin.utexas.edu.ORCID https://orcid.org/0000-0002-0515-7942
Oscar Y Franco-RochaLivestrong Cancer Institute, Dell School of Medicine, University of Texas at Austin, 1710 Red River St, Austin, TX, 78723, USA.
Manuela KogonStanford Center for Integrative Medicine, Stanford University School of Medicine, Palo Alto, CA, 94304, USA.
Sarah BraunVirginia Commonwealth University Massey Cancer Center, Richmond, VA, 23284, USA.
Leah TolbyDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, 94303, USA.
Ruth NyagakaVirginia Commonwealth University Massey Cancer Center, Richmond, VA, 23284, USA.
Alexa De La Torre SchutzLivestrong Cancer Institute, Dell School of Medicine, University of Texas at Austin, 1710 Red River St, Austin, TX, 78723, USA.
Douglas W BlayneyStanford Cancer Institute, Stanford Medicine, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, 94304, USA.
Oxana PaleshVirginia Commonwealth University Massey Cancer Center, Richmond, VA, 23284, USA.

Funding

Very-long Term Neurocognitive Outcomes in Breast Cancer Survivors (ProbC2)R01CA172145 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI KESLER, SHELLI R, PALESH, OXANA G · 2012 to 2024
$3.3M
Predicting Long-Term Chemotherapy-Related Cognitive ImpairmentR01CA226080 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI KESLER, SHELLI R, PALESH, OXANA G · 2019 to 2024
$3.1M
NCI NIH HHS R01 CA172145NCI NIH HHS R01 CA226080
6 · The paper itself

Abstract

purposeCognitive decline is common after cancer, but little is known regarding the etiology of this adverse effect, especially in terms of molecular mechanisms.

methodsThis prospective study obtained brain imaging and cognitive testing from 50 newly diagnosed women with primary breast cancer prior to any cancer treatment and 53 female controls. Participants completed up to seven assessments for a total time span of 9.7 ± 0.92 years. Imaging transcriptomics was used to measure the expression of genes in the brain involved in N-methyl-D-aspartate (NMDA) and calcium-mediated neurotransmission.

resultsGRIN2A, GRIN2B, and CACNA1C were significantly expressed in gray matter in both groups (R

conclusionThese findings suggest that gene expression involved in neurotransmission is disrupted in the brain among patients with breast cancer and may contribute to cognitive changes. Our results provide novel molecular insights regarding the roles of non-CNS cancer pathology and treatments in the brain related to NMDA signaling and pro-survival/plasticity-related pathways. Our findings also point to potential treatments for cognitive effects of cancer.

Indexed as

Breast NeoplasmsCalcium SignalingCognitive DysfunctionGray MatterReceptors, N-Methyl-D-AspartateAgedCalcium Channels, L-TypeCase-Control StudiesFemaleHumansMiddle AgedProspective StudiesCalcium Channels, L-TypeReceptors, N-Methyl-D-AspartateBrain transcriptomeCalcium signalingCancerCognitionGray matterNMDA receptor

Identifiers

PMID42402487
PMCPMC13333552

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.